The United States Food and Drug Administration (USFDA) has completed inspection Neuland Laboratories’ Unit 1 manufacturing facility at Bonthapally, Hyderabad. The inspection was conducted from June 17 to 21, 2019.
The inspection has been completed with five observations given under form 483. The company has already initiated corrective and preventive actions for the observations and is confident of satisfying the FDA within the stipulated time.
Neuland Laboratories manufactures active pharmaceutical ingredients for global pharmaceutical companies and provides end-to-end solutions for the pharmaceutical industry for chemistry-related services.